You are here: Industry Insights > Janssen

News List

Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen AmericanPharmaceuticalReview
February 15, 2022
Legend Biotech Corporation has achieved two milestones under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel)...
Lawsuit filed against J&J and Janssen for eye damage caused by Elmiron drug Pharmaceutical-Technology
January 28, 2022
Clinical trials started in 2018 recorded a link between Elmiron’s key ingredients and pigmentary maculopathy.
NOVA Expands JINKO Platform Pact with Janssen contractpharma
December 16, 2021
Implements its JINKO clinical trial simulation platform for the development of lung cancer models.
MHRA nod for Janssen’s relapsing multiple sclerosis drug Ponvory pharmatimes
August 12, 2021
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Ponvory (ponesimod) for the treatment relapsing multiple sclerosis (RMS).
Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights, August 2021 europeanpharmaceuticalreview
August 10, 2021
The EMA’s drug safety committee (PRAC) recommends updating risks of Janssen COVID-19 Vaccine, though the benefit-risk balance remains unchanged.
BioMed X, Janssen Begin Autoimmunity and Drug Delivery Research contractpharma
August 05, 2021
New research groups, PTA and TMI, aim to combat chronic inflammatory diseases and develop oral delivery of macromolar therapeutics.
BioMed X Institute Today Announces Two New Research Groups in Autoimmunity and Drug Delivery in Collaboration with Janssen b3cnewswire
August 03, 2021
German independent research institute BioMed X announces today the start of two new research projects with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Janssen's UPTRAVI IV FDA-Approved for PAH contractpharma
August 02, 2021
New therapeutic option allows patients to avoid short-term treatment interruptions and stay on UPTRAVI therapy.
NICE’s decision not to approve Zytiga ‘frustrating’, says ICR pharmatimes
July 16, 2021
The National Institute of Health and Care Excellence (NICE) has decided not to recommend Janssen’s Zytiga after reviewing its previous decision to reject the drug in 2020.
Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights, July 2021 europeanpharmaceuticalreview
July 14, 2021
The Pharmacovigilance Risk Assessment Committee (PRAC) provided safety warnings on COVID-19 vaccines, and found no evidence linking Zynteglo to blood cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page